|
STI-MED-SORB pharmaceutical plant is owned by AVVA RUS company.
 STI-MED-SORB Open Joint Stock Company was established on 20.06.1996, Resolution No. 474, registration No. 934, issued by Kirov Registration-Licensing Chamber Î.
The site is located in Kirov, 1000 km away from Moscow.
Production site is located in two block buildings, built in 1986, with total floor area 1188 sq.m. and 10200 sq.m. The buildings are connected with a gallery.
Total number of the site personnel – 294 people, including those engaged in:
|
Production |
158 people; |
|
Quality assurance and control |
44 people; |
|
logistic |
9 people. |
The company has a license for production of 55 pharmaceuticals formulations .
The production plant have 4 manufacturing sites:
“White tablet” production site – production of uncoated, coated tablets and pellets. Production capacity – 25 mln/month.
Capsule production site - production of pharmaceuticals in solid gelatin capsules. Production capacity – 15 mln/month.
“Dark tablet” production shop – production of pharmaceuticals based on hydrolyzed lignin. Production capacity – 24 mln/month.
API production site – production of hydrolyzed lignin. Production capacity – 16 tons/month.
STI-MED-SORB plant has its own research laboratory,R@D laboratory and a pilot lines.
Stages of Development
1996 – The beginning of production of Polifepan and Polifan- enterosorbents based on hydrolyzed lignin.
2000 – The beginning of modernization of STI-MED-SORB. Establishment of the technological line for production of various dosage forms.
2001 – Obtaining the license for production, storage and distribution of pharmaceuticals. Enhancement of tablets production. Development and production of Filtrum and Lactofiltrum branded products. Development and production of generic products.
2005 – Production of Aterostat hypolipidemic product and Motonium.
2006 – Production of Mikrazim, a highly effective pancreatine in microgranules, which successfully replace expensive imported analogues on the domestic pharmaceutical market.
Today, STI-MED-SORB conforms all requirements of GMP standards. Entire reconstruction of the production site has been completed, high-tech equipment has been installed, and integrated multi-level quality control system has been implemented. Research on development of new dosage forms jointly with research institutes is in place. A project on production of ointments, suppositories and syrups has been developed. | 
home
